Profile data is unavailable for this security.
About the company
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
- Revenue in USD (TTM)0.00
- Net income in USD-70.96m
- Incorporated2016
- Employees73.00
- LocationXilio Therapeutics Inc828 Winter Street, Suite 300WALTHAM 02451United StatesUSA
- Phone+1 (617) 430-4680
- Fax+1 (302) 655-5049
- Websitehttps://xiliotx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quince Therapeutics Inc | 0.00 | -30.28m | 30.28m | 32.00 | -- | 0.4082 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
Promis Neurosciences Inc | 0.00 | -11.89m | 30.53m | 6.00 | -- | 395.95 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
Raphael Pharmaceutical Inc | 0.00 | -1.57m | 30.79m | 0.00 | -- | -- | -- | -- | -0.0929 | -0.0929 | 0.00 | -0.0055 | 0.00 | -- | -- | -- | -624.25 | -- | -- | -- | -- | -- | -- | -- | -- | -173.44 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 31.84m | 4.00 | -- | 5.28 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
Xilio Therapeutics Inc | 0.00 | -70.96m | 31.86m | 73.00 | -- | 1.15 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 31.90m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
IGC Pharma Inc | 1.35m | -13.00m | 32.22m | 67.00 | -- | 3.88 | -- | 23.96 | -0.2168 | -0.2168 | 0.0229 | 0.1098 | 0.0993 | 0.292 | 18.42 | 20,074.63 | -96.01 | -42.46 | -113.83 | -46.07 | 54.50 | 20.95 | -966.54 | -730.00 | 0.9252 | -- | 0.0188 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
NKGen Biotech Inc | -100.00bn | -100.00bn | 32.60m | 63.00 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 32.96m | 163.00 | -- | 0.1615 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Aligos Therapeutics Inc | 13.79m | -99.59m | 33.00m | 67.00 | -- | 0.5565 | -- | 2.39 | -1.51 | -1.51 | 0.1796 | 0.7592 | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -- | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
ImmuCell Corp | 21.28m | -3.90m | 33.43m | 74.00 | -- | 1.35 | -- | 1.57 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Immuneering Corp | 0.00 | -54.18m | 33.51m | 65.00 | -- | 0.4257 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
Surrozen Inc | 0.00 | -37.58m | 35.15m | 42.00 | -- | 0.7684 | -- | -- | -18.44 | -18.44 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -67.75 | -- | -77.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Rock Springs Capital Management LPas of 31 Mar 2024 | 1.44m | 3.90% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 899.59k | 2.44% |
Balyasny Asset Management LPas of 31 Mar 2024 | 338.54k | 0.92% |
Columbia Investment Management Co. LLCas of 31 Dec 2023 | 249.64k | 0.68% |
Renaissance Technologies LLCas of 31 Mar 2024 | 249.45k | 0.68% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 221.91k | 0.60% |
FIL Investment Advisors (UK) Ltd.as of 31 Mar 2024 | 218.71k | 0.59% |
Geode Capital Management LLCas of 31 Mar 2024 | 84.83k | 0.23% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 71.08k | 0.19% |
Millennium Management LLCas of 31 Mar 2024 | 70.20k | 0.19% |